The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Prevention and Management of Intrathecal Drug Delivery and Spinal Cord Stimulation System Infections
Open accessAbstract
FULLY implantable devices or drug–device combinations, such as intrathecal drug delivery (DD) systems and spinal cord stimulation (SCS) systems, increasingly are used for the treatment of chronic intractable pain. 1,2Another approved indication for intrathecal DD systems is the administration of intrathecal baclofen (ITB) to treat medically intractable spasticity of spinal or cerebral origin. 3–5Although patients with cancer, spinal cord injuries, or cerebral palsy have a reduced life expectancy, the majority of intrathecal drug administration devices—and nearly all SCS devices—are implanted in patients with painful non–cancer-related disorders that are associated with a normal life span. Therefore, long-term implantable devices used for the treatment of pain and spasticity should have a relatively benign safety record. 6,7Device-related infection is the most common, potentially reducible, serious adverse event associated with intrathecal DD or SCS devices.Reducing the number of implantable DD and SCS device infections is important for various reasons. One is that treatment of an established infection often involves temporary or permanent removal of the device, which causes cessation of drug or stimulation therapy. Therapy cessation (with or without eventual device replacement) increases the risks, discomfort, inconvenience, and expenses of patients who experience infectious complications. Abrupt cessation of intrathecal drug therapy may precipitate drug withdrawal symptoms and, in the case of ITB, can have fatal consequences. 8In rare cases, device-associated infections can progress to fatal sepsis, meningitis, or both.Available data indicate that implantable DD and SCS device infections share important features with other surgical site infections (SSIs), including those that affect cerebrospinal fluid (CSF) shunts and electrophysiologic cardiac devices such as implantable pacemakers and cardioverter–defibrillators (ICDs). Management of infections associated with DD and SCS systems typically involves administration of antibiotics and explantation of the devices. Measures that reduce the incidence of other SSIs also should reduce the infection rate associated with the implantation of SCS and intrathecal DD devices.The authors reviewed data pertaining to infections associated with DD and SCS. Sources of data included published 1and unpublished clinical study data, postmarket and medical device reporting (MDR) data, published meta-analyses, US Centers for Disease Control (CDC) guidelines and other selected publications about prevention of SSIs, 9,10and pertinent studies from the CSF shunt infection literature 11–42and from the ICD infection literature. 43–51Clinical study data included information about implanted DD and neurostimulation systems marketed by Medtronic, Inc. (Minneapolis, MN). Information regarding device-related infections was available from three monitored multicenter device studies (model 8709 catheter, SynchroMed®10-ml pump, and IsoMed®pump) and one monitored multicenter study of an investigational intrathecal drug. The 8709 catheter study results were published previously. 1Results of the two pump studies and one intrathecal drug study are unpublished to date.The postmarket and MDR data included information about implanted DD and neurostimulation systems reported to the device manufacturer (Medtronic, Inc.), information which is reported also to the US Food and Drug Administration. The DD and SCS infection data analyzed in this review were reported between September 1, 2000, and July 1, 2002. Because of confidentiality regulations and voluntary reporting practices, it was not possible to audit postmarket surveillance data by comparing the information voluntarily reported by health-care professionals, patients, or both to original medical records. Such limitations undoubtedly caused cases of DD or SCS device–related infections to go unreported.Reasons for considering DD and SCS devices together and for including a focused review of the recent CSF shunt and ICD infection literature include the following: Allowing for the differences in patient populations, underlying disease states, and other factors—CSF shunts and DD devices both involve catheterization of the subarachnoid space with a fluid-conduit system and, like SCS, involve tunneling a portion of the implanted system subcutaneously between two anatomical sites. Neurosurgeons implant and manage virtually all patients with CSF shunts and implant a substantial proportion of DD and SCS devices. In general, neurosurgeons use similar methods to minimize the occurrence of infections associated with each type of implant surgery. ICD and SCS devices are similar to each other in size and appearance but are smaller than DD pumps. ICD implantation also involves tunneling from one anatomical site to another. Infection is a frequent, serious, and potentially reducible complication associated with implantation of all of these devices (DD, SCS, CSF shu
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290
Cited by
Clinical practice guidelines for antimicrobial prophylaxis in surgery
Bratzler, D. W., Dellinger, E. P., Olsen, K. M., Perl, T. M., Auwaerter, P. G., Bolon, M. K., Fish, D. N., Napolitano, L. M., Sawyer, R. G., Slain, D., et al. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp120568 · Cited by 2,591
Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery
Bratzler, D. W., Dellinger, E. P., Olsen, K. M., Perl, T. M., Auwaerter, P. G., Bolon, M. K., Fish, D. N., Napolitano, L. M., Sawyer, R. G., Slain, D., et al. (2013) · Surgical Infections · doi:10.1089/sur.2013.9999 · Cited by 1,197
Eldabe, S., Buchser, E., & Duarte, R. V. (2016) · Pain Medicine · doi:10.1093/pm/pnv025 · Cited by 403
Retrospective Review of 707 Cases of Spinal Cord Stimulation: Indications and Complications
Mekhail, N. A., Mathews, M., Nageeb, F., Guirguis, M., Mekhail, M. N., & Cheng, J. (2011) · Pain Practice · doi:10.1111/j.1533-2500.2010.00407.x · Cited by 332
Metadata
- Authors
- Follett, K. A., Boortz-Marx, R. L., Drake, J. M., DuPen, S., Schneider, S. J., Turner, M. S., & Coffey, R. J.
- Venue
- Anesthesiology
- Published
- 2004-06-01
- Volume
- 100
- Issue
- 6
- Pages
- 1582-1594
- ISSN
- 0003-3022 (ISSN-L)
- OpenAlex
- W2069010681
- Cited by
- 232
- References
- 1
- FWCI
- 9.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevention and Management of Intrathecal Drug Delivery and Spinal Cord Stimulation System Infections. https://app.cochat.ai/papers/10.1097/00000542-200406000-00034
- The paper
- Follett, K. A., Boortz-Marx, R. L., Drake, J. M., DuPen, S., Schneider, S. J., Turner, M. S., & Coffey, R. J. (2004). Prevention and Management of Intrathecal Drug Delivery and Spinal Cord Stimulation System Infections. Anesthesiology. https://doi.org/10.1097/00000542-200406000-00034
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.